Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  3. HSCS
H

HeartSciences Inc. (HSCS)

NCM – Цена в реальном времени. Валюта: USD

2.25

-0.06 (-2.60%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
25.03.2026

HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.

HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
24.03.2026

HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET.

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
16.03.2026

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
05.02.2026

University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.    (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company's MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology.

Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
29.01.2026

Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks. This collaboration will provide Cibolo Health's network of 123 independent hospitals across six states with access to a modern, cloud-native ECG management platform designed to improve workflow efficiency, data accessibility, and clinical decision-making.

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
15.12.2025

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update.

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
15.12.2025

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

Видео

No Data

There is no data to display